Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277882 | 0.90 | CYP3A4 (0.58) | CYP3A4PTGDR2TNFNOD2NOD1 | |
| SCHEMBL13521854 | 0.83 | CYP3A4 (0.74) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| Am-461 SCHEMBL29567409 | 0.83 | CYP3A4 (1.00) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| Am-461 SCHEMBL349848 | 0.83 | CYP3A4 (1.00) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL348737 | 0.82 | CYP3A4 (0.72) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| Am-461 SCHEMBL14715972 | 0.82 | CYP3A4 (0.98) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| Am-461 SCHEMBL14715969 | 0.82 | CYP3A4 (0.98) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL349853 | 0.81 | CYP3A4 (0.70) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL349956 | 0.81 | CYP3A4 (0.79) | CYP3A4PTGDR2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL1008947 | 0.80 | CYP3A4 (0.69) | CYP3A4PTGDR2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CYP3A4 1367/4885PTGDR2 2/4885TNF 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.